Related references
Note: Only part of the references are listed.The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients
Sushant Kumar et al.
MOLECULAR CANCER RESEARCH (2020)
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno et al.
NATURE MEDICINE (2020)
Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
Sonia Guedan et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes
Liqing Kang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
Kevin R. Parker et al.
CELL (2020)
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
CAR T-cells: costs, comparisons, and commentary
Annette E. Hay et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
Boris Gorovits et al.
BIODRUGS (2019)
Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies
Yu Zhao et al.
CLINICAL CANCER RESEARCH (2019)
Overcoming Challenges in Process Development of Cellular Therapies
Steven L. Highfill et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Metabolic Consequences of T-cell Costimulation in Anticancer Immunity
Alvaro Teijeira et al.
CANCER IMMUNOLOGY RESEARCH (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
Dwivedi Alka et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
Inmaculada Hernandez et al.
JAMA ONCOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
Kevin A. Hay
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Haiying Qin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
Yiyang Xu et al.
CELL DISCOVERY (2018)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights
Amrom E. Obstfeld et al.
BLOOD (2017)
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function
Nathan Singh et al.
CYTOTHERAPY (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
D. Sommermeyer et al.
LEUKEMIA (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy
Albert T. Gacerez et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations
Bajarang Vasant Kumbhar et al.
PLOS ONE (2016)
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
Lenka V. Hurton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
Nathan Singh et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Shannon L. Maude et al.
BLOOD (2016)
Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD
Annette Kuenkele et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
The HADDOCK web server for data-driven biomolecular docking
Sjoerd J. De Vries et al.
NATURE PROTOCOLS (2010)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
VBASE2, an integrative V gene database
I Retter et al.
NUCLEIC ACIDS RESEARCH (2005)
Share Paper
